Home » Healthcare » Australia Human Insulin Market

Australia Human Insulin Market

Australia Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Australia Human Insulin Market Size 2023	USD 155.81 million
Australia Human Insulin Market, CAGR	4.78%
Australia Human Insulin Market Size 2032	USD 237.50 million

Market Overview

Australia Human Insulin market size was valued at USD 155.81 million in 2023 and is anticipated to reach USD 237.50 million by 2032, at a CAGR of 4.78% during the forecast period (2023-2032).

The Australia human insulin market is primarily driven by the rising prevalence of diabetes, increasing awareness of effective diabetes management, and government initiatives to improve access to essential medicines. An aging population and growing obesity rates further contribute to the escalating demand for insulin therapies. Advancements in insulin formulations and delivery systems, such as insulin pens and pumps, are enhancing patient compliance and treatment outcomes. Additionally, the expansion of telemedicine and digital health platforms supports more efficient diabetes monitoring and management. Pharmaceutical companies are investing in research and development to introduce innovative biosimilar insulin products, making treatment more accessible and cost-effective. The growing adoption of personalized medicine and an increasing focus on preventive healthcare are also influencing market dynamics. Together, these factors are fostering sustained growth in the human insulin market across Australia, with stakeholders working collaboratively to meet the evolving needs of patients and healthcare providers.

The Australian human insulin market is characterized by a diverse geographic landscape, with key demand driven by urban regions such as New South Wales, Victoria, and Queensland, where the prevalence of diabetes is rising due to lifestyle factors and aging populations. Major pharmaceutical players like Novo Nordisk, Eli Lilly, and Sanofi dominate the market, providing a wide range of insulin formulations and delivery devices. Additionally, regional markets face unique challenges, including access to healthcare in rural and remote areas, where innovative solutions such as telemedicine and mobile clinics are being employed to reach underserved populations. Local players like Biocon and Wockhardt are also expanding their presence in the market through the introduction of biosimilars, increasing competition and making insulin therapies more accessible. Overall, the market’s dynamics are shaped by both global pharmaceutical giants and regional players working to meet the growing demand for diabetes management in Australia.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Australian human insulin market was valued at USD 155.81 million in 2023 and is projected to reach USD 237.50 million by 2032, growing at a CAGR of 4.78% from 2023 to 2032.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.

The increasing prevalence of diabetes, aging population, and rising obesity rates are key drivers for insulin demand.
Advancements in insulin delivery systems, including insulin pens and pumps, are contributing to enhanced patient compliance and treatment effectiveness.
The market is witnessing significant growth in the adoption of biosimilars, which offer cost-effective alternatives to branded insulin products.
Major competitors include global leaders like Novo Nordisk, Eli Lilly, Sanofi, and local players such as Biocon and Wockhardt.
Market restraints include high costs of advanced insulin therapies and challenges in rural healthcare access.
Regionally, New South Wales, Victoria, and Queensland dominate the market due to their larger diabetic populations and better healthcare infrastructure.

Report Scope

This report segments the Australia Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes and Related Health Conditions

One of the primary drivers of the human insulin market in Australia is the increasing prevalence of diabetes, particularly type 2 diabetes, which constitutes the majority of diagnosed cases. For instance, the Australian Bureau of Statistics reported that 5.3% of Australians approximately 1.3 million people were living with diabetes in 2022. According to data from the Australian Institute of Health and Welfare (AIHW), millions of Australians are currently living with diabetes, and this number is expected to grow due to lifestyle-related factors such as sedentary behavior, unhealthy diets, and rising obesity rates. The condition significantly impacts both the healthcare system and individual patients, requiring long-term management and consistent insulin therapy. As the diabetic population expands, the demand for human insulin as a fundamental treatment option continues to rise, propelling market growth.

Aging Population and Increased Life Expectancy

Australia’s aging population is another critical factor contributing to the growing demand for human insulin. For instance, life expectancy in Australia was 81.1 years for males and 85.1 years for females in 2021-2023. Older adults are at higher risk of developing type 2 diabetes due to age-related metabolic changes and a decline in pancreatic function. With Australia’s life expectancy ranking among the highest globally, the senior demographic is expanding rapidly. This demographic shift creates sustained pressure on healthcare resources and increases the requirement for effective diabetes management solutions. Consequently, the insulin market benefits from the consistent need for reliable, long-term treatment options among elderly patients, who often require more comprehensive therapeutic support.

Technological Advancements in Insulin Delivery Systems

Technological innovation in insulin delivery methods is significantly enhancing patient adherence and therapeutic outcomes, thus driving market growth. Traditional syringe-based insulin administration has largely been supplemented by more user-friendly solutions such as insulin pens, pumps, and continuous glucose monitoring (CGM) systems. These innovations provide greater convenience, reduce the risk of dosing errors, and improve the overall quality of life for patients. Australian healthcare providers and patients are increasingly adopting these modern delivery systems, supported by favorable reimbursement policies and educational programs. As the country continues to embrace digital health technologies and smart healthcare solutions, the human insulin market is poised for steady expansion.

Government Initiatives and Supportive Regulatory Framework

Government support and regulatory initiatives play a vital role in facilitating the accessibility and affordability of insulin in Australia. The Pharmaceutical Benefits Scheme (PBS) subsidizes a wide range of insulin products, making essential diabetes treatments more affordable for patients. Moreover, the Therapeutic Goods Administration (TGA) ensures that insulin products meet stringent safety and efficacy standards, fostering trust among healthcare professionals and consumers. Public health campaigns aimed at increasing diabetes awareness and early diagnosis also contribute to earlier intervention and greater demand for insulin therapies. These supportive policies, coupled with increased funding for chronic disease management, create a favorable environment for growth in the human insulin market.

Market Trends

Growing Preference for Insulin Analogs over Traditional Human Insulin

A key trend reshaping the human insulin market in Australia is the growing shift from conventional human insulin to insulin analogs. These analogs—such as rapid-acting (e.g., insulin lispro, insulin aspart) and long-acting variants (e.g., insulin glargine, insulin detemir)—offer pharmacokinetic profiles that closely mimic the body’s natural insulin response. Their advantages include quicker onset of action, extended duration, and reduced risk of hypoglycemia, making them particularly suitable for active and elderly patients alike. With increasing awareness among healthcare professionals and patients about the superior efficacy of analogs, their adoption is steadily rising. Pharmaceutical companies continue to invest in research and development to enhance analog formulations, which is expected to further accelerate the transition and fuel long-term market growth.

Strengthening Government Support and Public Health Initiatives

Government involvement remains a central driver in shaping market trends and ensuring insulin accessibility. For instance, the Australian government continues to invest in national programs such as the Pharmaceutical Benefits Scheme (PBS) and the National Diabetes Services Scheme (NDSS), which subsidize a wide range of insulin products and diabetes management tools. These programs play a crucial role in reducing financial barriers for patients and promoting regular treatment adherence. Additionally, public health initiatives aimed at early diagnosis, diabetes education, and lifestyle modification are gaining momentum, leading to more proactive disease management. Such supportive infrastructure and policies are instrumental in sustaining demand and fostering a conducive environment for innovation within the insulin market.

Advancement and Adoption of Insulin Delivery Technologies

Another prominent trend is the integration of advanced insulin delivery technologies into routine diabetes care. For instance, insulin pens, patch pumps, and continuous subcutaneous insulin infusion (CSII) devices are replacing traditional vial-and-syringe methods, improving patient adherence and treatment outcomes. These innovations reduce the complexity of insulin administration and enhance patient adherence by offering greater control and flexibility. The Australian healthcare system is progressively supporting the uptake of these technologies through subsidy programs and educational campaigns, particularly targeting children, adolescents, and individuals with complex diabetes needs. As digital health continues to evolve, connected insulin pens and smart glucose monitors are also gaining traction, paving the way for more personalized and data-driven treatment plans.

Market Entry and Growth of Biosimilar Insulin Products

The rise of biosimilar insulin products marks a transformative trend in Australia’s insulin landscape. With the patent expiration of several branded insulin products, biosimilar manufacturers are entering the market with cost-effective alternatives that offer comparable quality, safety, and efficacy. These products have the potential to significantly reduce treatment costs for both the healthcare system and patients, thereby improving access to essential insulin therapies. Australian regulatory authorities, including the Therapeutic Goods Administration (TGA), are providing clear guidelines and support for biosimilar approvals, encouraging market competition and innovation. As healthcare providers grow more confident in prescribing biosimilars, their uptake is expected to increase substantially in the coming years.

Market Challenges Analysis

High Cost of Advanced Insulin Therapies and Limited Affordability

One of the most pressing challenges in the Australian human insulin market is the high cost associated with advanced insulin analogs and modern delivery systems. For instance, reports indicate that while the Pharmaceutical Benefits Scheme (PBS) subsidizes a range of insulin products, not all advanced insulin therapies and delivery devices are fully covered, leaving some patients with significant out-of-pocket expenses. While these therapies offer improved patient outcomes and convenience, they come with a significantly higher price tag compared to traditional human insulin. This cost barrier can lead to delayed treatment initiation, reduced adherence, and increased risk of diabetes-related complications. Furthermore, the introduction of newer analogs and innovative technologies often outpaces public funding updates, limiting access for some segments of the population. As a result, cost remains a significant constraint on equitable access to optimal diabetes care, hindering the market’s full growth potential.

Complex Regulatory Pathways and Market Entry Barriers for Biosimilars

Another critical challenge is the regulatory and commercial complexity involved in the approval and market penetration of biosimilar insulin products. Although biosimilars offer a cost-effective alternative to branded insulin, their development requires significant investment in clinical trials, manufacturing quality assurance, and compliance with Australia’s rigorous regulatory standards set by the Therapeutic Goods Administration (TGA). This process can delay market entry and limit the number of competitors in the space, reducing the anticipated cost benefits for patients and the healthcare system. Additionally, there remains some hesitancy among healthcare professionals and patients regarding the interchangeability and long-term safety of biosimilars, despite clinical evidence supporting their efficacy. These barriers slow down adoption rates and hinder the widespread impact that biosimilars could have in driving down insulin prices. Addressing these regulatory and educational challenges is essential to encourage competition and improve affordability in the Australian human insulin market.

Market Opportunities

The Australia human insulin market presents substantial opportunities driven by the increasing prevalence of diabetes and a growing emphasis on chronic disease management. With lifestyle-related health issues such as obesity and sedentary behavior on the rise, the diabetic population is expected to expand steadily in the coming years. This trend creates a sustained demand for insulin therapies, particularly for type 2 diabetes, which accounts for the majority of cases. Additionally, the rising health consciousness among Australians and improved screening practices are leading to earlier diagnoses, resulting in a growing number of individuals requiring long-term insulin treatment. These developments offer pharmaceutical companies the opportunity to expand their product portfolios and reach a wider patient base through targeted awareness and accessibility initiatives.

Furthermore, the market is poised for growth through advancements in technology and the emergence of biosimilar insulin products. As digital health and remote patient monitoring gain traction, there is an increasing opportunity to integrate smart insulin delivery devices with mobile health platforms, enabling personalized and data-driven diabetes care. These innovations can significantly improve treatment adherence and patient outcomes, while also opening avenues for partnerships between pharmaceutical companies and tech developers. Additionally, the introduction and broader acceptance of biosimilar insulin present a cost-effective alternative to branded products, encouraging market competition and improving accessibility, particularly in underserved regions. With strong regulatory support, government funding programs, and a focus on value-based care, the Australian human insulin market offers a fertile ground for growth, innovation, and long-term investment.

Market Segmentation Analysis:

By Device:

The Australian human insulin market is segmented by device into pens, syringes, and others, with insulin pens emerging as the dominant segment. Insulin pens are widely preferred due to their ease of use, accurate dosing, portability, and patient-friendly design, especially among individuals requiring regular insulin administration. Their growing adoption is supported by government initiatives and patient education programs that emphasize better glycemic control and self-management of diabetes. Syringes, while traditional and cost-effective, are gradually being phased out in favor of more modern and convenient delivery systems. However, they still retain relevance in specific patient demographics, particularly among those with long-standing diabetes who are accustomed to conventional methods. The “others” category, which includes insulin pumps and jet injectors, is gaining momentum due to advancements in wearable technology and continuous insulin delivery. These innovations, although not yet as widely adopted, are seeing increased interest, especially among type 1 diabetic patients and younger populations seeking more integrated diabetes management solutions.

By Indication:

By indication, the human insulin market in Australia is categorized into type 1 diabetes, type 2 diabetes, and gestational diabetes, with type 2 diabetes accounting for the largest market share. The rising incidence of type 2 diabetes—driven by aging, obesity, and sedentary lifestyles—continues to fuel consistent demand for insulin therapies, especially among patients who fail to achieve glycemic control through oral medications alone. Type 1 diabetes, though less prevalent, represents a stable and significant segment that relies heavily on daily insulin therapy for survival. Patients with type 1 diabetes typically begin insulin treatment at an early age and require long-term management, thereby ensuring steady demand. Gestational diabetes, while a smaller market segment, is gaining attention due to increased maternal health awareness and early screening practices. As more healthcare providers advocate for insulin therapy in high-risk pregnancies, this segment is projected to grow steadily. Overall, the diverse indication landscape offers multiple growth avenues tailored to specific patient needs and treatment protocols.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

New South Wales
Victoria
Queensland
Western Australia (WA)
South Australia

Regional Analysis

New South Wales (NSW)

New South Wales holds the largest share in the Australian human insulin market, accounting for approximately 32% of the total market. As the most populous state in the country, NSW has a high concentration of diabetic patients, particularly in metropolitan areas like Sydney, where access to healthcare infrastructure is robust. The state benefits from widespread awareness campaigns, early diabetes screening programs, and extensive healthcare coverage, which collectively drive strong demand for both human insulin and advanced insulin delivery systems. Public and private healthcare collaborations have further strengthened diabetes management programs, enabling consistent monitoring and timely intervention. In addition, the prevalence of sedentary lifestyles in urban regions contributes to rising cases of type 2 diabetes, further supporting the market’s upward trajectory. With a proactive approach to public health and ongoing investments in medical technology, NSW continues to lead the nation in insulin adoption and usage.

Victoria

Victoria follows closely behind NSW with a 25% share of the Australian human insulin market. The state has a well-developed healthcare system and a growing diabetic population, particularly in cities like Melbourne. Government-funded initiatives under the Victorian Diabetes Strategy have strengthened early detection and prevention measures, leading to increased demand for insulin products across both type 1 and type 2 diabetes segments. Victoria is also known for its active research institutions and medical technology hubs, which contribute to innovation in insulin delivery methods and patient education tools. Moreover, the state has demonstrated a high uptake of insulin pens and newer technologies, driven by both provider recommendation and patient preference. With strong community support services and access to subsidized diabetes management programs, Victoria remains a key market for pharmaceutical companies and healthcare providers looking to expand their insulin offerings.

Queensland

Queensland represents around 18% of the national human insulin market. The state’s mix of urban and rural populations creates unique challenges and opportunities in insulin distribution and access. While metropolitan areas like Brisbane benefit from strong healthcare infrastructure, regional and remote communities often face barriers in accessing consistent diabetes care. To address this, Queensland Health has implemented mobile clinics, telemedicine initiatives, and expanded pharmaceutical outreach programs, all of which contribute to growing insulin demand across the state. The rise in diabetes prevalence, particularly in Indigenous and aging populations, further supports market expansion. Additionally, Queensland’s climate and active lifestyle culture have led to an increased focus on preventive care, encouraging earlier diagnosis and insulin therapy where needed.

Western Australia (WA)

Western Australia accounts for approximately 12% of the Australian human insulin market. Despite its relatively smaller population, WA has seen a steady increase in diabetes cases, particularly among its aging demographic and in Indigenous communities. The government has prioritized rural health access, with efforts to improve the distribution of diabetes care services across the state’s vast geography. Telehealth services, state-funded screening campaigns, and targeted Indigenous health initiatives have helped identify and manage cases earlier, contributing to increased insulin demand. Urban centers like Perth have also seen rising adoption of advanced insulin delivery systems, supported by public awareness and access to specialist care. WA’s strategic health policies and focus on equitable access continue to position it as a steadily growing contributor to the national insulin market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co.
Eli Lilly and Company
Boehringer Ingelheim

Competitive Analysis

The Australian human insulin market is highly competitive, with several key players vying for market share. Novo Nordisk, Eli Lilly, Sanofi, Biocon, MannKind Corporation, Pfizer, Wockhardt, Lupin, Tonghua Dongbao Pharmaceutical Co., and Boehringer Ingelheim lead the market, offering a wide range of insulin products to meet the needs of the growing diabetic population. Companies are increasingly focusing on innovation, particularly in insulin formulations and delivery methods, to meet the rising demand driven by the growing diabetic population. The market is dominated by both traditional insulin therapies and newer insulin analogs, which are preferred due to their superior efficacy and lower risk of hypoglycemia. Advancements in insulin delivery devices, such as insulin pens, pumps, and continuous glucose monitoring systems, are also shaping the competitive landscape by enhancing patient convenience and treatment adherence. Biosimilar insulin products have emerged as a key factor in intensifying competition, offering cost-effective alternatives to branded insulin, thereby increasing accessibility for patients. Companies are also exploring new technologies such as inhaled insulin and connected devices that offer more personalized diabetes management solutions. Partnerships and collaborations are common strategies, as firms seek to strengthen their position in the market. Additionally, the growing focus on patient education and government-funded programs has created an environment ripe for growth, allowing companies to tap into both urban and rural markets.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The Australian human insulin market exhibits moderate to high market concentration, with a few dominant global players holding a significant share of the market. These companies, through their strong brand recognition, extensive product portfolios, and robust distribution channels, maintain a competitive edge. The market is characterized by a growing preference for insulin analogs over traditional human insulin due to their improved efficacy, reduced risk of hypoglycemia, and enhanced patient convenience. This shift is driving innovation in insulin formulations and delivery systems, including the increasing adoption of insulin pens and pumps. Furthermore, the entry of biosimilar insulin products has intensified competition, offering cost-effective alternatives that increase accessibility for patients, particularly in the public healthcare sector. The market is also shaped by the increasing focus on patient-centric solutions, including integrated diabetes management systems, which enhance treatment adherence and improve overall outcomes. The competitive landscape continues to evolve, with both established and emerging players striving for market dominance.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The market is projected to experience steady growth, driven by an increasing diabetic population and advancements in insulin therapies.
Technological innovations, such as smart insulin pens and connected glucose meters, are enhancing diabetes management and patient adherence.
The adoption of continuous glucose monitoring (CGM) systems is expected to rise, offering real-time data for better glycemic control.
Biosimilar insulin products are gaining traction, providing cost-effective alternatives and improving accessibility for patients.
Government initiatives and subsidies are anticipated to expand, making advanced diabetes care more affordable and widespread.
Personalized medicine approaches, utilizing genetic and lifestyle data, are likely to become more prevalent in insulin therapy.
The integration of artificial intelligence in insulin delivery systems is set to enhance treatment precision and outcomes.
Collaboration between healthcare providers and technology companies is expected to foster innovation in diabetes management solutions.
Public awareness campaigns are anticipated to increase, promoting early detection and proactive management of diabetes.
The market will continue to evolve, focusing on patient-centric solutions and striving to meet the diverse needs of individuals with diabetes.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. Australia Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by Australia 32

5.1.1. Australia Human Insulin Market Import Volume/Revenue, By Australia, 2018 – 2023 32

5.2. Export Analysis by Australia 33

5.2.1. Australia Human Insulin Market Export Volume/Revenue, By Australia, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by Australia 34

6.1.1. Australia Human Insulin Market Demand Volume/Revenue, By Australia, 2018 – 2023 34

6.2. Supply Analysis by Australia 35

6.2.1. Australia Human Insulin Market Supply Volume/Revenue, By Australia, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by Australia 36

7.1.1. Australia Human Insulin Market Production Volume/Revenue, By Australia, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. Australia Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. Australia Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. Australia Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. Australia Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. Australia Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. Australia Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. Australia Human Insulin Market Company Volume Market Share, 2023 43

11.3. Australia Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

Australia Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – AUSTRALIA ANALYSIS 92

18.1. Type 92

18.1.1. Australia Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. Australia Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. Australia Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. Australia Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. Australia Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. Australia Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. Australia Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. Australia Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. Australia Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. Australia Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Boehringer Ingelheim 99

19.1.14. Company 10 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. Australia Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Australia Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for Australia Human Insulin Market 30

FIG NO. 4. Australia Human Insulin Market Import Volume/Revenue, By Australia, 2018 – 2023 32

FIG NO. 5. Australia Human Insulin Market Export Volume/Revenue, By Australia, 2018 – 2023 33

FIG NO. 6. Australia Human Insulin Market Demand Volume/Revenue, By Australia, 2018 – 2023 34

FIG NO. 7. Australia Human Insulin Market Supply Volume/Revenue, By Australia, 2018 – 2023 35

FIG NO. 8. Australia Human Insulin Market Production Volume/Revenue, By Australia, 2018 – 2023 36

FIG NO. 9. Australia Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. Australia Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. Australia Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. Australia Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. Australia Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. Australia Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. Australia Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. Australia Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. Australia Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. Australia Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. Australia Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. Australia Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. Australia Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. Australia Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. Australia Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. Australia Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. Australia Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. Australia Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. Australia Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. Australia Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. Australia Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. Australia Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. Australia Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. Australia Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : Australia Human Insulin Market: Snapshot 18

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24

TABLE NO. 4. : Australia Human Insulin Market Revenue, By Type, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : Australia Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : Australia Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : Australia Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : Australia Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : Australia Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : Australia Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : Australia Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : Australia Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : Australia Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : Australia Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the Australia Human Insulin?

The Australia Human Insulin market was valued at USD 155.81 million in 2023 and is projected to reach USD 237.50 million by 2032.

What factors are driving the growth of the Australia Human Insulin?

Key drivers include the rising prevalence of diabetes, aging population, obesity, and advancements in insulin delivery technologies.

What are some challenges faced by the Australia Human Insulin?

Major challenges include high costs of advanced insulin therapies and regulatory hurdles for biosimilars.

Who are the major players in the Australia Human Insulin?

Key players include Novo Nordisk, Eli Lilly, Sanofi, Biocon, Wockhardt, Pfizer, and MannKind Corporation.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –